Supernus Pharmaceuticals, Inc. (SUPN) · Nov 2, 2026 · Acquisition

Supernus merger closes, launching larger CNS company with $650M debt

$1B merger close — 1.5401 shares per Supernus share; $1.0B special dividend; $650M term loan

Supernus completes its merger with Indivior, creating a broader CNS drug company. The deal was expected, but closes with $650 million of new term debt.

Supernus was already a commercial CNS company building around nine U.S. products, including Qelbree, GOCOVRI, ZURZUVAE and newly launched ONAPGO; the announced Indivior combination was designed to create an approximately $2.2 billion-revenue, 11-product platform with expected annual cost synergies.

The transaction is now operational, not merely announced. Supernus confirms the merger has closed and the combined company has launched, with Supernus’ headquarters, Jack Khattar as CEO and an evenly split eight-member board. 〔0〕 This removes closing and approval risk, but the core terms were already disclosed and expected for the fourth quarter, so the announcement itself is largely confirmation rather than a fresh strategic surprise.

The main new economic reality is the balance-sheet burden funding Indivior holders’ cash payout. The combined company is using a $650 million term loan and existing cash to fund the $1.0 billion special dividend. That was also part of the announced structure, but it means the promised scale and synergy benefits must now be delivered while the new company carries additional debt and absorbs two operating organizations.

Control lands slightly more with legacy Indivior shareholders, despite the merger-of-equals framing. Former Indivior holders own approximately 56.5% and former Supernus holders 43.5% of the combined company. 〔1〕 That is consistent with the pre-announced exchange ratio and ownership split, so it changes governance in practice but not the market’s prior understanding of the deal.

Deal termsAt closeComparison
Exchange ratio (Merger terms)1.5401 shares—
Special dividend (Merger terms)$1.0B—
Term loan (Financing terms)$650M—
Former Indivior ownership (Ownership)56.5%—
Former Supernus ownership (Ownership)43.5%—

Bottom line: This is a meaningful business transition, but not a meaningful surprise: the planned CNS combination has closed on its announced terms. The upside case now depends on integration and synergies, while the immediate complication is the debt and cash used to fund the special dividend.

What to watch next

Combined-company first earnings report

Original filing on SEC EDGAR

More Supernus Pharmaceuticals, Inc. news

Supernus merger closes, launching larger CNS company with $650M debt | SUPN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.